![]() ![]() (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced results of the PHYOX™2 pivotal clinical trial of nedosiran, an investigational GalXC™ RNAi candidate for the treatment of primary hyperoxaluria (PH), in a late-breaker poster presentation at the American Society of Nephrology (ASN) Kidney Week 2021. ![]() LEXINGTON, Mass.-( BUSINESS WIRE)- Dicerna Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |